Status:
UNKNOWN
Exploring the Preventive Effect of Mitochondrial Protective Agent Idebenone on Post-stroke Epilepsy
Lead Sponsor:
Xiangya Hospital of Central South University
Conditions:
Post Stroke Epilepsy
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
According to the random number table, all patients were divided into short-term treatment group, long-term treatment group and non-intervention stroke control group according to the proportion of (1:1...
Eligibility Criteria
Inclusion
- Patients admitted to hospital within 24 hours of stroke symptoms and diagnosed with stroke (including cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, intracranial venous sinus thrombosis, etc.) after relevant examinations;
- Able to cooperate with the inspection;
- Sign the informed consent form.
Exclusion
- History of epilepsy before stroke;
- A history of serious comorbidities that may lead to seizures (including malignant tumors, specific autoimmune diseases, severe electrolyte abnormalities, end-stage renal disease, and severe head trauma);
- Secondary stroke caused by head trauma or surgery;
- Other patients that the researchers think need to be excluded.
Key Trial Info
Start Date :
July 5 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
2700 Patients enrolled
Trial Details
Trial ID
NCT05987397
Start Date
July 5 2023
End Date
December 31 2025
Last Update
August 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Xiangya Hospital, Central South University
Changsha, Hunan, China, 410008